

### Basic Principles of Cancer Immunotherapy

#### David Kwasny, PharmD, BCOP Manager, Clinical Pharmacy – Norton Cancer Institute







Society for Immunotherapy of Cancer

Association of Community Cancer Centers



### Disclosures

- Disclosures: Participant on speakers bureau for Amgen, Boehringer-Ingelheim, Genentech, and Seattle Genetics.
- I will not be discussing non-FDA approved indications during my presentation.







# The Premise of Cancer Immunotherapy

- Normally, the immune system eliminates mutated and/or damaged cells
- To exist, tumors must evolve mechanisms to locally disable and/or evade the immune system.

# The goal of immunotherapy is to restore the capacity of the immune system to recognize and reject cancer.








# Why Does the Immune System Fail to Eliminate Cancer?

- Cancer cells grow progressively in immunocompetent hosts without evidence of <u>T cell exhaustion</u> or <u>systemic anergy</u>
  - **T cell Exhaustion:** CD8+ T cells often become dysfunctional, entering a state known as exhaustion, during certain chronic infections or when they enter a suppressive tumor microenvironment
  - **Systemic Anergy:** A state of immune unresponsiveness. Induced when the T cell's antigen receptor is stimulated, effectively freezing T cell responses pending a "second signal" from the antigen-presenting cell







Normal cell Highly immunogenic transformed cell Poorly immunogenic and immunoevasive transformed cell






sitc

















Normal cell
 Highly immunogenic transformed cell
 Poorly immunogenic and immunoevasive transformed cell
















### Multi-layered Immunosuppression

- Tumors insulate themselves with dense layers of immunosuppressive stroma
- Overcoming the many layers of interconnected and often functionally redundant immune suppressive mechanisms represents a daunting challenge for tumor-specific T cells
- Immunotherapy can "peel back" the layers of local immune suppression, thereby restoring the capacity of T cells to eradicate the tumor










# Types of Immunotherapy










# **T cell Checkpoint Modulation**








ACCC



# Antigen-specific T cell Activation










# **T Cell Checkpoint Modulation**

- To exist, tumors must evolve mechanisms to locally disable and/or evade the immune system.
- The goal of T cell checkpoint blockade is to make T cell "off-switches" inaccessible to tumor cells, thus restoring tumor-specific immunity.




issociation of Community Concer Center

Society for Immunotherapy of Cance



# The CTLA-4 Checkpoint

- <u>Cytotoxic T-Lymphocyte</u>
  <u>A</u>ssociated Protein <u>4</u>
- Also known as CD152
- Negative regulator of T cell activation










# Anti-CTLA-4 induces regression of transplantable colon carcinoma




Enhancement of antitumor immunity by CTLA-4 blockade. Science. 217(5256): 1734-6.







# Ipilimumab (human anti CTLA-4)



sito

Society for Immunotherapy of Cance


wasiation of Community Concer Center

 Granted FDA approval for treatment of patients with metastatic melanoma in 2010



# The PD-1/PD-L1 Checkpoint

- Promotes T cell tolerization through inhibiting activation signaling
- T cell PD-1 interacts with PD-L1 and PD-L2
- Many cells express PD-L1/PD-L2 and can suppress T cell activation
- Tumors express PD-L1 through two primary mechanisms
  - TIL production of IFN-y
  - Oncogenic signaling pathways









#### Anti-PD-1 Slows Tumor Growth in Pre-clinical Models

• PD-1 deletion or inhibition reduced CT26 colon cancer cell growth in BALB/c mice







Iwai et al. Internat. Immunol 2004








# **Therapeutic Cancer Vaccines**

 The goal of therapeutic cancer vaccination is to increase the immunogenicity of tumor antigens in order to generate a high frequency of tumorspecific T cells.










# **Components of a Cancer Vaccine**










# An intra-nasal HPV E6/E7: α-GalCer vaccine slows growth of TC-1 tumors












4-1BB agonist antibody and HPV E6/E7 vaccine synergize in curing TC-1 Tumors




Todd Bartkowiak, M.S.







#### Intratumoral Injection of Innate Immune Agonists: Direct Vaccination Approach



Days after innoculation of cells








# **Adoptive Cell Transfer**

 The goal of adoptive cell transfer is to overwhelm the tumor with a higher frequency of tumorspecific immune cells and/or engineer immune cells to target cancer










# **Adoptive Cell Therapy Process**

sitc


Society for Immunotherapy of Cancer








#### CD19 CAR T Cell Therapy for Relapsed B Cell ALL



Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N, Chew A, Gonzalez V, Zheng Z, Lacey S, et al. 2014. Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine. 374(10): 998.










Effector Antibodies and Antibodydrug Conjugates (ADCs)

 The goal of effector antibodies is to specifically target and kill tumor cells using innate mechanisms which are difficult to evade of suppress and/or through delivery of cytotoxic agents









# Key ADC/Antibody Principles


- **Specificity:** The more tumor specific the target antigen is, the higher the agent can be dosed without limiting toxicity
- Internalization: The target tumor surface protein must internalize to deliver the toxin it should do so frequently and to a suitable endosomal compartment
- Stability: The toxin must remain inert and tethered to the antibody until it is delivered to its target cell





# **Oncolytic Viruses**

 The goal of an oncolytic virus is to specifically target and kill tumor cells through viral replication










# **Combination Immunotherapies**






Association of Community Cancer Center



#### Combination Immunotherapies Dual CTLA-4 and PD-1 inhibition










#### **Combination Immunotherapies** *Chemotherapy can induce an immune response*






#### **Combination Immunotherapies** *Radiotherapy can induce an immune response*


sito

Society for Immunotherapy of Cancer





# **Immunotherapy Biomarkers**












#### **Further Resources**



**demos**MEDICAL

#### SOCIETY FOR IMMUNOTHERAPY OF CANCER







sitc

Society for Immunotherapy of Cancer